News and insights

NMPA (China) approves Tyvyt + chemotherapy to treat first line metastatic gastric or gastroesophageal junction adenocarcinoma. - Innovent Biologics -+ Eli Lilly

Results from pivotal MOUNTAINEER trial demonstrating clinically meaningful antitumor activity of Tukysa + Trastuzumab in previously treated HER2-positive metastatic colorectal cancer.-Seagen Inc. + Merck Inc.

NMPA (China) approves Cresemba to treat invasive aspergillosis and invasive mucormycosis.- Pfizer + Basilea Pharmaceutica

MHRA (UK) approves Yselty to treat symptoms of uterine fibroids.- ObsEva SA.

Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions. Novartis.

MHLW (Japan) accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older.- GSK

NMPA (China) approves Kerendia to treat chronic kidney disease associated with type 2 diabetes.- Bayer

Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19b beta-containing vaccine.

Novavax statement on prototype vaccine’s broad immune responses and accelerated focus on Omicron BA.4/5 as recommended by the FDA.

NMPA (China) approves cadonilimab injection for the treatment of relapsed or metastatic cervical cancer. Akeso Inc.

Positive results of phase III ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB).- Basilea Pharmaceutica

APeX-2 and APeX-S trials of Orladeyo shows reductions in attack and quality of life benefits in hereditary angioedema.- BioCryst Pharma

Submission of NDA to the FDA for Paxlovid full approval.- Pfizer

Patient enrollment of phase III tolebrutinib trials for multiple sclerosis + myasthenia gravis paused in the U.S. -Sanofi

Eylea injection sBLA for every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review.- Regeneron.

New long-term follow-up clinical data for 3-antigen adult hepatitis B vaccine presented at EASL 2022.-VBI Vaccines Inc.

Updates on ongoing NDA submission for vamorolone in Duchenne muscular dystrophy.- Santhera Pharma

Imfinzi plus chemotherapy before surgery significantly improved pathologic complete response in AEGEAN phase III trial in resectable non-small cell lung cancer.- AstraZeneca

FDA approves LungFit PH for persistent pulmonary hypertension of the newborn.- Beyond Air

Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral brepocitinib in dermatomyositis and lupus

EU approves Xenpozyme for Niemann-Pick disease.- Sanofi

EU approves Yescarta for relapsed or refractory follicular lymphoma.- Kite Pharma

EU approves Nexviadyme for Pompe disease.- Sanofi

FDA issues Complete Response for SPR 994 in complicated urinary tract infection.- Spero Therapeutics

Altamira Therapeutics receives FDA 510(k) clearance for Bentrio to treat allergic rhinitis.

Ipsen acquires Epizyme and with it Tazverik

CHMP recommends Vegzelma (bevacizumab biosimilar).- Celltrion

Clinical value beyond price alone: anti-TNF biosimilars enable early treatment

Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases

Clinical value beyond price alone: biosimilars improve patient access to treatment

Long-term topical management of psoriasis: the road ahead

Over the horizon: early stage trials for NASH

Phase II trials and stem cell therapies

The next global epidemic

The latest treatments in NASH

The future of organ transplantation

Complications of stem cell transplants

Challenges in transplant organ rejection

Treating rejection in organ transplants

Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups

Antibody-drug conjugates (ADCs)

Cancer immunotherapies

Left ventricular assist devices – A viable therapeutic option for heart failure?

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

How close are we to a disease-modifying treatment for Alzheimer’s?

Biologic efficacy for complications associated with moderate-to-severe psoriasis

Moderate-to-severe psoriasis: treatment for young women

Chronic myelogenous leukaemia: a remarkable success story

Unravelling the microbiome - health through happy communities

Part two | New hopes for treatment in the global obesity epidemic

Inactivity in the elderly increases their cardiovascular risk by 14%

Type 2 diabetes risk may be increased by statin use in susceptible individuals

New hyperammonaemia resource developed for Medthority.com users

Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?

Launch of updated Hypogonadism Knowledge Centre

Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet

Key findings from the SWIPE study

Focus on Primary Care - helping GPs diagnose, manage and treat urticaria

Free haemato-oncology report added to AIKN-IFI congresses section

Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre

Part Three | Next generation obesity therapies

Medical cannabis - a novel approach to pain control

Immobility and sleep disruption in the ICU - Latest recommendations

ESOT 2015 speaker slides added to AIKN-IFI

Prof Vincent interview - Defining the eCASH Concept in PAD Management

New: Symposium videos & presentations for immunologists, dermatologists and allergists

Appetite and the brain - white matter integrity to blame?

Magnetic nanoparticles could help rejuvenate damaged hearts

Metastatic melanoma: the new immunotherapies

SGLT2 Inhibitors: good news for diabetes

Long-term disease control in Psoriasis: announcing a new project

Targeted therapies in triple negative breast cancer

Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease

Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future

Opioids - Over the horizon

From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)

New approaches to anticoagulant therapy

Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)

Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre

Horizons: a series of opinion & insight articles on disruptive healthcare in practice

Launch of Chronic Spontaneous Urticaria CME activity

New findings may pave the way for novel HIV drugs

ATS 2015 symposium materials added to COPD Knowledge Centre

Replacement therapies for opioid drugs in pain treatment

Launch of new Cystic Fibrosis Knowledge Centre

Parkinson's disease: the struggle to control symptoms

Acute myeloid leukaemia: Hope for new treatments

Adoptive T cell therapy, advanced melanoma and survival

An independent review of current treatments for migraine

Launch of LAL-Deficiency Knowledge Centre

Migraine treatments: On the horizon

Psoriasis Knowledge Centre relaunches on Medthority.com

New rare disease platform launched for Hunter Syndrome

Vitamin D in pregnancy - is it any good?

New type 2 diabetes CME activity now available on Medthority.com

Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com

IL-17A treatment section added to Psoriasis Knowledge Centre

Close social relationships may slow cognitive decline

Microbiomes: is there nothing that they can't do?

Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries

Senolytics: Can we treat age-related diseases with a single drug

Opioids: the future and challenging the epidemic

New inflammatory bowel disease (IBD) Knowledge Centre

Opioids: The war on drugs

Targeted therapies in HER2 positive breast cancer

Atopic Dermatitis Knowledge Centre launched on Medthority.com

New publication digest and infographic for Cardiologists.

Exciting developments and new approaches in psoriasis

Genetic variation and drug efficacy - could this pave the way for personalised medicines?

Shaken not stirred your bacteriophage cocktail

WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre

Bedwetting resource receives a mobile-friendly transformation

Breast Cancer- Targeted therapies

Launch of Oral Anticoagulation Reversal Knowledge Centre

NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com

COPD experts tackle key topics in our latest Q&A

World Congress of Dermatology 2019 - A new ERA for global Dermatology

UPDATE: Urticaria e-learning new modules & symposia highlights

Nonalcoholic steatohepatitis: the next global epidemic?

Migraine: The forgotten epidemic?

Your guide to IBD novel treatments and assessment tools

Launch of new Chronic Lymphocytic Leukaemia CME

Schizophrenia: challenges in a crowded market

Targeted therapies in HER2 negative breast cancer

The way ahead for cystic fibrosis

Japan's aging population and Alzheimer's